Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + ifosfamide + mesna + mitoxantrone hydrochloride liposome + etoposide
- Development stage
- Unknown
- Lead developer
- Jiangsu Provincial People's Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Modified R-MINE is a combination chemotherapy regimen consisting of rituximab, ifosfamide, mesna, mitoxantrone hydrochloride liposome (PLM60), and etoposide. Developed by The First Affiliated Hospital with Nanjing Medical University, this regimen is specifically designed for patients with late relapsed diffuse large B-cell lymphoma (DLBCL). The key innovation is the substitution of conventional mitoxantrone with a liposomal formulation (PLM60), which aims to enhance efficacy and reduce cardiotoxicity. Rituximab targets CD20-positive B-cells, while ifosfamide, mitoxantrone, and etoposide act as cytotoxic agents through DNA alkylation, intercalation, and topoisomerase II inhibition. Mesna is included to prevent hemorrhagic cystitis associated with ifosfamide use.
- Other names
- Modified R-MINE regimenR-MINE (modified)PLM60-modified R-MINEPLM-60-modified R-MINEPLM 60-modified R-MINE
02
Targets
Beyond the preview
Go deeper on rituximab + ifosfamide + mesna + mitoxantrone hydrochloride liposome + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + ifosfamide + mesna + mitoxantrone hydrochloride liposome + etoposide.